- Home
- FINS vs PBYI Comparison
FINS vs PBYI Comparison
Compare FINS & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FINS | PBYI |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 418.0M | 467.2M |
| IPO Year | 2018 | 2011 |
Fundamental Metrics
Financial Performance| Metric | FINS | PBYI |
|---|---|---|
| Price | $12.02 | $9.62 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 38.0K | ★ 255.1K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.08 |
| Revenue | N/A | ★ $27,685,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $122.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.15 | $4.58 |
| 52 Week High | $13.45 | $9.98 |
Technical Indicators
Market Signals| Indicator | FINS | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 63.11 |
| Support Level | N/A | $7.56 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.31 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 79.65 |
Price Performance
Historical ComparisonAbout FINS Angel Oak Financial Strategies Income Term Trust of Beneficial Interest
Angel Oak Financial Strats Income Term Trust is a non-diversified, closed-end management investment company. The fund's objective is to seek current income with a secondary objective of total return. In pursuing its investment objective, the fund invests mainly in debt issued by financial institutions, including subordinated debt, unrated debt, senior debt, and high-yield securities.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.